|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida (D.K.W., C.S., R.L.P.); and Department of Chemistry, University of Florida, Gainesville, Florida (N.A.H.)
We have shown previously that a highly conserved Tyr in the nicotinic acetylcholine receptor (nAChR) ligand-binding domain (LBD) (
7 Tyr188 or
4 Tyr195) differentially regulates the activity of acetylcholine (ACh) and the
7-selective agonist 3-(4-hydroxy,2-methoxybenzylidene)anabaseine (4OH-GTS-21) in
4β2 and
7 nAChR. In this study, we mutated two highly conserved LBD Trp residues in human
7 and
4β2 and expressed the receptors in Xenopus laevis oocytes.
7 Receptors with Trp55 mutated to Gly or Tyr became less responsive to 4OH-GTS-21, whereas mutation of the homologous Trp57 in β2 to Gly, Tyr, Phe, or Ala resulted in
4β2 receptors that showed increased responses to 4OH-GTS-21. Mutation of
7 Trp55 to Val resulted in receptors for which the partial agonist 4OH-GTS-21 became equally efficacious as ACh, whereas
4β2 receptors with the homologous mutation remained nonresponsive to 4OH-GTS-21. In contrast to the striking alterations in agonist activity profiles that were observed with mutations of
7 Trp55 and β2 Trp57, mutations of
7 Trp149 or
4 Trp154 universally resulted in receptors with reduced function. Our data support the hypothesis that some conserved residues in the nAChR LBD differentially regulate receptor activation by subtype-selective agonists, whereas other equally well conserved residues play fundamental roles in receptor activation by any agonist. Residues like
7 Trp149 (
4 Trp154) may be considered pillars upon which basic receptor function depends, whereas
7 Trp55 (β2 Trp57) and
7 Tyr188 (
4 Tyr195) may be fulcra upon which agonists may operate differentially in specific receptor subtypes, consistent with the hypothesis that ACh and 4OH-GTS-21 are able to activate nAChR in distinct ways.
Address correspondence to: Roger L. Papke, Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL 32610-0267. E-mail: rlpapke{at}ufl.edu